Biomarker based patient selection for proteasome inhibitor treatment
AssigneeUniversity of Utah Research Foundation
InventorsJacob M. Winter, Jared Rutter
Life of this patent
Estimating the term…
Abstract
Disclosed are any of the methods or compositions herein. Disclosed are methods of treating a subject having cancer comprising administering a proteasome inhibitor to the subject having cancer, wherein the subject having cancer has a non-functional ATAD1 gene. Disclosed are methods of diagnosing and treating cancer, the method comprising: diagnosing a subject as being susceptible to treatment by a proteasome inhibitor; and administering a proteasome inhibitor to the subject.
Claims22
A method of treating a subject having cancer comprising administering a proteasome inhibitor to the subject having cancer, wherein the subject having cancer has a non-functional ATAD1 gene.
The method of any of the preceding claims, wherein a portion or all of the ATAD1 gene is deleted.
The method of any of the preceding claims, wherein a portion of all of the PTEN gene is deleted.
The method of any of the preceding claims, wherein the subject has breast cancer, lung cancer, colon cancer, brain cancer, or prostate cancer.
A method of diagnosing and treating cancer in a subject, the method comprising:
- a) diagnosing a subject as being susceptible to treatment by a proteasome inhibitor;
- and
- b) administering a proteasome inhibitor to the subject.
The method of any of the preceding claims, wherein subject having a non-functional ATAD1 gene is a subject having a portion of all of the ATAD1 gene deleted.
The method of any of the preceding claims, wherein subject having a non-functional PTEN gene is a subject having a portion of all of the PTEN gene deleted.
A method of increasing apoptosis in a subject comprising administering a proteasome inhibitor to the subject, wherein the subject comprises a non-functional ATAD1 gene.
The method of any of the preceding claims, wherein the subject has cancer.
The method of any of the preceding claims, wherein the proteasome inhibitor is bortezomib, ixazomib or carfilzomib.
A method of comprising the steps in the following order:
- (a) obtaining a sample from a cancer patient;
- (b) determining whether the subject has a non-functional ATAD1 gene in the sample;
- (c) identifying the cancer patient as a suitable candidate for treatment with a proteasome inhibitor if the subject has a non-functional ATAD1 gene;
- and
- (d) administering a proteasome inhibitor to the cancer patient identified as the suitable candidate, and not administering a proteasome inhibitor to the cancer patient if the cancer patient does not have a non-functional ATAD1 gene.
A method of enhancing the efficacy of a proteasome inhibitor in a subject with cancer, the method comprising administering to the subject an effective amount of a proteasome inhibitor to a subject with a non-functional ATAD1 gene.
Dependencies are inferred from the claim text.